The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).
G. R. Blumenschein
Consultant or Advisory Role - Bayer
Research Funding - Bayer
J. R. Molina
Research Funding - Bayer
C. D. Lathia
Employment or Leadership Position - Bayer
T. J. Ong
Employment or Leadership Position - Bayer
D. Roth
Employment or Leadership Position - Bayer
P. Rajagopalan
Employment or Leadership Position - Bayer
F. V. Fossella
Research Funding - Bayer
M. S. Kies
Research Funding - Bayer
R. S. Marks
No relevant relationships to disclose
A. A. Adjei
Research Funding - Bayer
P. R. Sundaresan
Employment or Leadership Position - Bayer